Why Light AI's $5M Funding to Advance FDA-Tracked Medical Diagnostics

John Luna and the team at Light AI are tackling one of the most persistent friction points in primary care: diagnostic latency. By developing QuickScan, a software-only platform that leverages AI algorithms to analyze images from standard smart devices, they are removing the requirements for proprietary hardware or invasive testing (e.g., no swabs or lab tests). This engineering feat hinges on computer vision and the97% accuracy rate in pre-FDA validation studies—specifically achieving a 100% Negative Predictive Value for viral vs. bacterial pharyngitis differentiation. The core innovation here is not just 'AI for health,' but the move toward decentralized diagnostic software that can betaped directly to existing consumer hardware. This $5M private placement from MV Capital will facilitate the critical ISO 13485/QMS audit and Health Canada registration, which are non-negotiable regulatory hurdles for a Class II medical device submission in both the Canadian and domestic markets. Transitioning leadership to John Luna earlier this year saw the platform move into its pivotal FDA clinical trial phase for QuickScan Strep A, marking a shift from R&D development to rigorous, regulated production readiness.